Rheumatology Network Reviews Why Patients Resist Treatment With DMARDs
NORWALK, Conn., Sept. 24, 2013 /PRNewswire/ -- UBM Medica US announces that Rheumatology Network features a special podcast highlighting a particular treatment challenge facing people with rheumatic diseases such as rheumatoid arthritis. Expert guidelines are unanimous that patients with rheumatic disorders, especially those with rheumatoid arthritis, should have early treatment with drugs called DMARDs (disease-modifying anti-rheumatic drugs) which reduce inflammation and slow joint damage; however, fully a third of patients who might benefit from these drugs are not taking them.
Although studies suggest that socioeconomic factors such as cost and level of education may be the primary reason, one important explanation may be simpler to resolve, rheumatologist Richard Martin MD explains in a podcast on Rheumatology Network . In the largest study to address the question, Dr. Martin and his coworkers found that cause may be a simple failure of communication: Many patients appear to resist the idea of taking a new DMARD because they have difficulty dealing with information about medical care (independent of ethnicity or education level), and may make incorrect assumptions about the drugs based on inaccurate understanding.
The new podcast on Rheumatology Network provides advice and resources to help them quickly assess how well individual patients are able to understand, evaluate, and act on this information.
About UBM Medica USAddressing today's healthcare information needs, UBM Medica US, delivers strategic, integrated communications solutions and comprehensive reach -- online, in print, and via custom programs. Improving the effectiveness of healthcare through information and education, UBM Medica US provides unbiased clinical, practical, and business information for physicians, providers, payers, and patients around the world. Through journals, magazines, websites, online communities, drug databases, digital events, and other valuable resources, UBM Medica US also delivers comprehensive communication solutions for the pharmaceutical and related industries. Websites include CancerNetwork.com, ConsultantLive.com, DiagnosticImaging.com, RheumatologyNetwork.com, OBGYN.net, PhysiciansPractice.com, PsychiatricTimes.com and SearchMedica.com. UBM Medica US is part of UBM Connect – which provides marketing services across a number of communities, the largest of which are healthcare, medical device design and advanced manufacturing. UBM Connect also includes UBM Studios, the global leader in interactive digital environments. UBM Connect is a UBM plc company. For more information, visit www.UBMMedicaUS.com.About UBM plcUBM plc is a global events-led marketing services and communications company. We help businesses do business, bringing the world's buyers and sellers together at events and online, as well as producing and distributing news and specialist content. Our 5,500 staff in more than 30 countries are organized into expert teams which serve commercial and professional communities, helping them to do business and their markets to work effectively and efficiently. For more information, go to www.ubm.com; follow us on Twitter at @UBM_plc to get the latest UBM corporate news. Media contact: Jason J. GoldenContent Marketing Manager203-523-7040 email@example.com SOURCE UBM Medica US
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts